Dr. Zifeng Wang obtained her master’s degree from the joint program of the Chinese Academy of Sciences & ShanghaiTech University, where her research focused on the identification and function of non-coding RNAs in breast cancer. Subsequently, Zifeng was awarded a Ph.D. in Biology from the Center for Personalized Cancer Therapy (CPCT), a collaborative venture between the University of Massachusetts Boston and the Dana-Farber/Harvard Cancer Center (DF/HCC). Her doctoral thesis uncovered novel aspects of LSD1/SETD7-mediated epigenetic reprogramming as key drivers of prostate cancer progression. Zifeng’s research interests are in understanding epigenetic dysregulation, particularly in chromatin remodeling and the role of pioneer transcription factors in tumor development and cell identity evolution. Outside the lab, she enjoys hiking, driving, traveling, reading, home cleaning and arrangement, and gardening. Welcome Zifeng!